 Home > Active Ingredient News > Antitumor Therapy > Cancer Commun: Paclitaxel Liposome + Cisplatin vs. Gemcitabine + Cisplatin First-line Therapeutic Efficacy of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung: A Multicenter Randomized Controlled Study

Cancer Commun: Paclitaxel Liposome + Cisplatin vs. Gemcitabine + Cisplatin First-line Therapeutic Efficacy of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung: A Multicenter Randomized Controlled Study

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

what paclitaxel

pure source 3

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Cancer Communications published the results of a phase 3 clinical study led by Professor Zhou Caicun of Shanghai Pulmonary Hospital, which mainly evaluated paclitaxel liposomes + cisplatin (LP) vs gemcitabine + cisplatin (GP) as the first-line treatment for locally advanced stages.
Or metastatic lung squamous cell carcinoma (LSCC)
.

The main purpose is to evaluate the efficacy of paclitaxel liposome + cisplatin (LP) vs gemcitabine + cisplatin (GP) in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma (LSCC)

The included patients are between 18 and 75 years old, locally advanced (clinical stage IIIB, not suitable for concurrent radiotherapy and chemotherapy or surgery) or metastatic (stage IV) LSCC, according to the solid tumor response evaluation criteria (version 1.
1), in the use of this Before the study drug treatment, there was no previous systemic chemotherapy and at least one measurable lesion
.

The primary endpoint is progression-free survival (PFS)

540 patients underwent eligibility screening and were randomized to receive the LP regimen (n = 268) or the GP regimen (n = 272)

73.

The last follow-up date was December 10, 2019, and the median follow-up time was 15.

PFS and OS

Subgroup analysis

There was no significant difference between the LP group and the GP group in ORR (LP: 41.
8% vs.
GP: 45.
9%, P=0.
412) and DCR (LP: 90.
3% vs.
GP: 88.
1%, P= 0.
443)
.

There was no significant difference between the LP group and the GP group in ORR (LP: 41.

Efficacy evaluation

97.
7% of the patients in the LP group and 99.
6% of the patients in the GP group reported any grade of AEs
.

SAE occurred in 31.

97.

Adverse reactions

In summary, studies have shown that for patients with locally advanced or metastatic LSCC, the PFS, OS, ORR, and DCR of the LP regimen are similar to those of the GP regimen, but have more favorable toxicity
.

Studies have shown that for patients with locally advanced or metastatic LSCC, the PFS, OS, ORR and DCR of the LP regimen are similar to those of the GP regimen, but have more favorable toxicity

Original source:

Zhang J, Pan Y, Shi Q, et al.

Zhang J, Pan Y, Shi Q, et al.
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study.
Cancer Commun (Lond).
2021 Oct 26.
doi: 10.
1002/cac2.
12225.
Epub ahead of print.
PMID: 34699693.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.